Presentation on theme: "GAP - Overall Goal Facilitates and administers MD Anderson's Sister Institution Network (the largest network of cancer centers) working collaboratively."— Presentation transcript:
GAP - Overall Goal Facilitates and administers MD Anderson's Sister Institution Network (the largest network of cancer centers) working collaboratively on education, research, patient care aimeing at lessening the world's cancer burden
MDACC Global Academic Programs Sister Institution Network (N= 26)
SINF National Breast Cancer Foundation: $300,000
1.Yang W, Xia Y, Ji H, Zheng Y, Liang J, Huang W, Gou X, Aldape K, Lu Z. Nuclear PKM2 regulates β-catenin transactivation upon EGFR activation. Nature, 480(7375):118–22, 2011. 2.Dietrich S, Glimm H, Andrulis M, Kalle von C, Ho AD, Zenz T. BRAF inhibition in refractory hairy-cell leukemia. N Engl J Med, 366(21):2038–40, 2012. 3.Yang W, Xia Y, Hawke D, Li X, Liang J, Xing D, Aldape K, Hunter T, Alfred Yung WK, Lu Z. PKM2 Phosphorylates Histone H3 and Promotes Gene Transcription and Tumorigenesis. Cell, 150(4):685–96, 2012. 4.Zhang M, Maiti S, Bernatchez C, Huls H, Rabinovich B, Champlin RE, Vence LM, Hwu P, Radvanyi L, Cooper LJ. A New Approach to Simultaneously Quantify Both TCR - and -Chain Diversity after Adoptive Immunotherapy. Clin Cancer Res, 18(17):4733–42, 2012.
Nasopharyngeal Carcinoma Impact of Post-Rx EBV Titer on Outcome Chan et al., JNCI 94: 1614, 2002 (Chinese University of Hong Kong) Validation: Lin et al., NEJM, 2004 (Taiwan); Le et al., CCR, 2004 (US) <500 copies >500 copies
Credentialing & QA: IMRT H&N Phantom Primary PTV 4 cm diameter 4 TLD Secondary PTV 2 cm diameter 2 TLD Organ at risk 1 cm diameter 2 TLD Axial and sagittal radiochromic films 1º PTV treated to 6.6 Gy 2º PTV treated to 5.4 Gy OAR limited to < 4.5 Gy Secondary PTV Primary PTV Organ at Risk Designed in collaboration with RTOG; Molineu et al, IJROBP, October 2005 MDACC (P01 funded)
EBV Assay An International Collaboration to Harmonize the Quantitative Plasma Epstein-Barr Virus (EBV) DNA Assay for Future Biomarker-Guided Trials in Nasopharyngeal Carcinoma Le QT 1, Zhang Q 2, Cao HB 1, Cheng AJ 3, Pinsky BA 1, Hong RL 4, Chang JT 3, Wang CW 4, Kuo-Chien Tsao KC 3, Lo YMD 6, Lee N 5, Ang KK 7, Chan ATC 6, Chan AKC 6 1 Stanford University, 2 RTOG Statistical Center, 3 Chang-Gung University, 4 National Taiwan University Hospital, 5 Memorial Sloan Kettering Cancer Center, 6 The Chinese University of Hong Kong, 7 M.D. Anderson Cancer Center